Figure 1

VEGF expression after in vitro treatment with bevacizumab. Both 10 and 100 μg/mL bevacizumab decreased the level of VEGF in C4-2B only, compared with control IgG. There were significant differences in the VEGF levels between the 10 or 100ug/ml bevacizumab and control IgG (P < 0.01). Human bone metastatic prostate cancer cell co-cultured with human microvessel cell expressed 6 times more VEGF than did tumor cultured cell only, and this level significantly decreased after treatment with 10 or 100 μg/mL bevacizumab.